Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.

J Clin Oncol · 2020 · PMC7527156 · PMID 32749941

Europe PMC DOI

hedged sentences

0.2460

closest p · 4.9× alpha

0.2460

boldest claim

The sentences

did not reach statistical significanceP = .246not close (p > 0.1)

Although patients with NSMP EC seemed to benefit from CTRT (5-year RFS: 79.7% with CTRT v 67.7% with RT; 5-year OS: 89.3% v 87.6%), this did not reach statistical significance (RFS: HR, 0.68, 95% CI, 0.36 to 1.30, P = .246; OS: HR, 0.68, 95% CI, 0.26 to 1.77, P = .434; Fig 3 ).

also in 111,027 other papers

highly significantno p-value reported

Furthermore, patients with p53abn EC had a highly significant benefit from CTRT with an absolute benefit of 22.4% and 23.1% for 5-year RFS and OS, respectively, whereas patients with POLE mut EC had an excellent survival in both treatment arms.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.